Exicure, Inc. XCUR
We take great care to ensure that the data presented and summarized in this overview for EXICURE, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding XCUR
View all-
Abingworth LLP London, X0282KShares$92,9390.11% of portfolio
-
Carlyle Group Inc. Washington, DC282KShares$92,9390.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny65.6KShares$21,6480.0% of portfolio
-
Geode Capital Management, LLC Boston, MA56.5KShares$18,6510.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA40.1KShares$13,2300.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny34.8KShares$11,4840.0% of portfolio
-
Virtu Financial LLC New York, NY27KShares$8,9240.0% of portfolio
-
Two Sigma Securities, LLC New York, NY22.7KShares$7,4900.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il18.2KShares$5,9920.0% of portfolio
-
Bank Of America Corp Charlotte, NC12.8KShares$4,2240.0% of portfolio
Latest Institutional Activity in XCUR
Top Purchases
Top Sells
About XCUR
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Insider Transactions at XCUR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 16
2024
|
Josh Miller Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
46
-2.52%
|
$0
$0.52 P/Share
|
|
Feb 29
2024
|
Dgp Co., Ltd. |
SELL
Open market or private sale
|
Direct |
3,400,000
-100.0%
|
$3,400,000
$1.32 P/Share
|
|
Feb 16
2024
|
Josh Miller Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
46
-2.46%
|
$0
$0.6 P/Share
|
|
Nov 16
2023
|
Josh Miller Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
38
-1.99%
|
$0
$0.56 P/Share
|
|
Aug 16
2023
|
Josh Miller Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
37
-1.9%
|
$0
$0.83 P/Share
|
|
Jun 23
2023
|
Cbi Usa, Inc. |
SELL
Conversion of derivative security
|
Direct |
3,400,000
-80.6%
|
$3,400,000
$1.6 P/Share
|
|
May 16
2023
|
Josh Miller Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
185
-8.67%
|
$185
$1.07 P/Share
|
|
Dec 15
2022
|
Cbi Usa, Inc. |
BUY
Open market or private purchase
|
Direct |
3,400,000
+44.63%
|
$3,400,000
$1.6 P/Share
|
|
May 19
2022
|
Bali Muralidhar Director |
BUY
Open market or private purchase
|
Indirect |
1,472,126
+14.84%
|
$0
$0.19 P/Share
|
|
Dec 21
2021
|
Gates Frontier, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,268,619
-20.03%
|
$0
$0.24 P/Share
|
|
Nov 15
2021
|
Douglas E. Feltner Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+33.33%
|
$0
$0.91 P/Share
|
|
Nov 15
2021
|
David A Giljohann Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+16.25%
|
$0
$0.91 P/Share
|
|
Aug 27
2021
|
Elias D. Papadimas Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
10,000
+50.0%
|
$10,000
$1.38 P/Share
|
|
May 14
2021
|
Douglas E. Feltner Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+50.0%
|
$7,500
$1.27 P/Share
|
|
May 14
2021
|
David A Giljohann Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+19.4%
|
$7,500
$1.27 P/Share
|
|
May 14
2021
|
Matthias Schroff Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+50.0%
|
$7,500
$1.27 P/Share
|
Last 12 Months Summary
| Conversion of derivative security | 3.4M shares |
|---|---|
| Payment of exercise price or tax liability | 167 shares |
| Open market or private sale | 3.4M shares |